AU3899893A - Compositions for the treatment of acute or chronic inflammation - Google Patents

Compositions for the treatment of acute or chronic inflammation

Info

Publication number
AU3899893A
AU3899893A AU38998/93A AU3899893A AU3899893A AU 3899893 A AU3899893 A AU 3899893A AU 38998/93 A AU38998/93 A AU 38998/93A AU 3899893 A AU3899893 A AU 3899893A AU 3899893 A AU3899893 A AU 3899893A
Authority
AU
Australia
Prior art keywords
acute
compositions
treatment
chronic inflammation
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU38998/93A
Inventor
Siamon Gordon
Michael Stein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of AU3899893A publication Critical patent/AU3899893A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU38998/93A 1992-04-06 1993-04-06 Compositions for the treatment of acute or chronic inflammation Abandoned AU3899893A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929207732A GB9207732D0 (en) 1992-04-06 1992-04-06 Wound repair
GB9207732 1992-04-06

Publications (1)

Publication Number Publication Date
AU3899893A true AU3899893A (en) 1993-11-08

Family

ID=10713696

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38998/93A Abandoned AU3899893A (en) 1992-04-06 1993-04-06 Compositions for the treatment of acute or chronic inflammation

Country Status (3)

Country Link
AU (1) AU3899893A (en)
GB (1) GB9207732D0 (en)
WO (1) WO1993019770A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680628B2 (en) * 1992-08-20 1997-08-07 Schering Corporation Novel uses of IL-4 and/or IL-10, and antibodies against the same

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7449186B1 (en) 1990-08-02 2008-11-11 Fred Hutchinson Cancer Research Center Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies
US5827670A (en) * 1990-08-02 1998-10-27 Fred Hutchinson Cancer Research Center Methods of isolating and detecting bone marrow stromal cells with VCAM-1-specific antibodies
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US6706264B1 (en) 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
GB2304047A (en) * 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
JP2003533488A (en) 2000-05-12 2003-11-11 ベス・イスラエル・ディーコニス・メディカル・センター・インコーポレーテッド Compositions and methods for achieving immunosuppression
EP1406855A4 (en) 2001-06-13 2006-04-19 Teva Gyogyszergyar Reszvenytar Novel process for preparing rac-bicalutamide and its intermediates
US7102026B2 (en) 2001-06-13 2006-09-05 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Process for preparing and isolating rac-bicalutamide and its intermediates
EP2452688A1 (en) * 2010-11-12 2012-05-16 Ruprecht-Karls-Universität Heidelberg Use of interleukine 10 RNA transfected macrophages in anti-inflammatory therapies
EP2776460B1 (en) 2011-11-08 2018-05-02 UMC Utrecht Holding B.V. Fusion protein comprising an interleukin 4 and interleukin 10
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
WO2014004465A1 (en) 2012-06-25 2014-01-03 The Brigham And Women's Hospital, Inc. Targeted therapeutics
CN114144194A (en) 2019-04-19 2022-03-04 斯纳凯恩制药私人有限责任公司 Fusion protein containing IL13

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680628B2 (en) * 1992-08-20 1997-08-07 Schering Corporation Novel uses of IL-4 and/or IL-10, and antibodies against the same

Also Published As

Publication number Publication date
GB9207732D0 (en) 1992-05-27
WO1993019770A1 (en) 1993-10-14

Similar Documents

Publication Publication Date Title
AU3548795A (en) Benzopyranopyrazolyl derivatives for the treatment of inflammation
AU3201095A (en) Substituted thiazoles for the treatment of inflammation
AU4623193A (en) Corrosion inhibition composition
AU5860396A (en) Substituted oxazoles for the treatment of inflammation
AU2388895A (en) Substituted cyclopentadienyl compounds for the treatment of inflammation
AU3716193A (en) Pharmaceutical compositions
AU3899893A (en) Compositions for the treatment of acute or chronic inflammation
AU2424895A (en) Substituted spirodienes for the treatment of inflammation
AU1430492A (en) Pharmaceutical composition for the treatment of gastritis
AU3236093A (en) The use of ob-101 to treat inflammation
AU3235693A (en) The use of ob-104 to treat inflammation
AU3842693A (en) Coating compositions
AU5853894A (en) Use of vitamin d glycosides for the treatment or prevention of osteoporosis
EP0577023A3 (en) Angiotensin-ii receptor-antagonists for the treatment of arrhythmices
AU6396394A (en) Products of the inhibition of advanced glycosylation
AU2649092A (en) Desulphurisation treatment
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
AU4220193A (en) Deazaaminopterins for treatment of inflammation
AU5270693A (en) Pharmaceutical composition for preventing or treating arteriosclerosis
AU6274694A (en) Methods and compositions for the inhibition of complement activation
AU5371694A (en) Use of the tarchonanthus camphoratus
IL105285A0 (en) Compositions for the treatment of diabetes
AU5699396A (en) Compositions for the treatment of skin conditions
AU4314393A (en) Synergistic biocide-agent combinations
AU5957794A (en) Compositions and method for the inhibition of phagocytes